Izotropic Corporation is positioning its IzoView Breast CT Imaging System to disrupt the $8.7 billion breast imaging market with significantly lower pricing and advanced technology. The system targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioned at $500,000 versus competitors priced up to $1.5 million.
The technology offers true 360-degree 3D imaging without compression, bridging the clinical gap between standard screening and MRI. The system provides 100x greater spatial resolution than MRI at significantly lower cost, addressing fundamental imaging challenges in compression-based imaging like mammography.
Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast tissue. Dense breast tissue creates imaging challenges where overlapping structures can mask cancers, potentially delaying diagnosis when cancers are small and in their most treatable stages. This limitation represents an $8 billion annual burden in follow-up procedures, repeat imaging, and unnecessary interventions driven by inconclusive results from current screening technologies.
The platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades available at https://www.BioMedWire.com. This creates scalable revenue expansion without hardware replacement, offering long-term value and adaptability to evolving clinical needs.
Izotropic Corporation trades on the CSE under symbol IZO and on the OTCQB under symbol IZOZF. The company's development of this transformational approach through its IzoView system represents a significant advancement in breast imaging technology that could substantially reduce healthcare costs while improving diagnostic accuracy for millions of women worldwide.
